Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow BAX
Baxter International Inc. (BAX) Shares outstanding
Baxter International Inc.'s shares outstanding at the end of fiscal 2025 was $513.0M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $518.0M. Over the past ten years it has ranged from $504.0M (fiscal 2022) to $555.0M (fiscal 2017); the current reading is higher than 45% of that period. Baxter International Inc. ranks 3rd of 50 Medical Instruments & Supplies companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $513.0M | 0.59% |
| FY2024 | $510.0M | 0.39% |
| FY2023 | $508.0M | 0.79% |
| FY2022 | $504.0M | (0.79%) |
| FY2021 | $508.0M | (1.74%) |
| FY2020 | $517.0M | (0.39%) |
| FY2019 | $519.0M | (4.95%) |
| FY2018 | $546.0M | (1.62%) |
| FY2017 | $555.0M | 0.73% |
| FY2016 | $551.0M | 0.36% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $518.0M | 0.58% |
| Mar 2026 | $515.0M | 0.39% |
| Dec 2025 | $513.0M | (0.19%) |
| Sep 2025 | $514.0M | 0.00% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| AVTR Avantor, Inc. compare | $677.2M |
| BAX Baxter International Inc. | $518.0M |
| BLCO Bausch + Lomb Corporation compare | $357.1M |
| COO The Cooper Companies, Inc. compare | $193.4M |
| SOLV Solventum Corporation compare | $173.3M |
| ALGN Align Technology, Inc. compare | $71.5M |
| WST West Pharmaceutical Services, Inc. compare | $71.3M |
| ATR AptarGroup, Inc. compare | $64.2M |
| RGEN Repligen Corporation compare | $56.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BAX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement